Skip to main content

Kotra Industries Berhad (0002.KL)

KLS Healthcare Drug Manufacturers - Specialty & GenericView data quality →
57.2Fair

ValueMarkers Composite Index

Top 64%#15,926 of 44,714
Undervalued

54% below intrinsic value ($2)

UndervaluedFair ValueOvervalued
Piotroski
4/9
Neutral
Beneish
-2.01
Investigate
Altman
7.51
Safe
DCF Value
$2
Undervalued
ROIC
13.6%
Adequate
P/E
14.1
Value
Updated: ·Source: Data sourced from SEC filings and institutional providers. Not financial advice.·Report data issue

Kotra Industries Berhad (0002.KL) — VMCI valuation read

Composite valuation read on 0002.KL: VMCI 57/100 against a Healthcare sector median of 50. The 7-point above-median print is the headline number for Kotra Industries Berhad, and at the mid-cap tier it reflects how the five pillars combine into a single decision-grade score.

Trailing 30-day insider activity for 0002.KL: nothing material on SEC EDGAR. With the Form 4 channel quiet, the price-vs-DCF gap and the trailing margin trend carry more weight in the active read.

**Investor frame.** Value, quality, risk in three lines on 0002.KL: 0002.KL trades at 21.0x earnings, 17% above the Healthcare median of 18.0x; ROIC of 17.0% sits 7.0pp above the Healthcare median (10.0%); net debt to EBITDA of 2.9x is the rate-sensitivity line to watch. EV/EBITDA at 14.0x versus 12.0x for Healthcare closes the value frame.

0002.KL fell 1.8% over the trailing 7 days, with a +3.0% read on a 30-day basis.

Top peers ranked by VM Score. Compare valuation, quality, and risk metrics across the sector.

Browse More

Key metrics explained

Definitions, formulas, and how ValueMarkers calculates each indicator used in 0002.KL’s VM Score.

Explore More

Compare Competitors

Weekly Stock Analysis - Free

5 undervalued stocks, fully modeled. Every Monday. No spam.

Cookie Preferences

We use cookies to analyze site usage and improve your experience. You can accept all, reject all, or customize your preferences.